drugs
Measles eradicated in the UK, according to WHO
September 28, 2017Medical Communications UK, WHO, biotech, drugs, measles, pharma, pharmaceutical
The measles virus has been eliminated from the UK for the first time in the country’s history, according to the …
Improved heart attack test could save millions for NHS
September 27, 2017Research and Development biotech, drugs, heart attack, pharma, pharmaceutical
A new research, funded by the British Heart Foundation, has led to the creation of a new heart attack test …
Devastation to Puerto Rico threatens global medicine supply
September 27, 2017Medical Communications, Research and Development Puerto Rico, biotech, drugs, pharma, pharmaceutical
The destructive forces of Hurricane Maria have caused untold damage to the island nation, with a reported 13 people left …
Axovant shares capitulate after Alzheimer’s drug failure
September 26, 2017Research and Development Alzheimer's, Axovant, biotech, drugs, pharma, pharmaceutical
Axovant Sciences was set up with just one drug candidate in its portfolio, and a risky one, at that. The …
New CMO hops onto Bicycle Therapeutics
September 26, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bicycle Therapeutics, GSK, Pfizer, biotech, drugs, pharma, pharmaceutical
Bicycle Therapeutics has moved to appoint industry veteran, Maria Koehler, to the position of Chief Medical Officer at the company. …
FDA pointedly rejects Intellipharma’s opioid painkiller
September 26, 2017Manufacturing and Production, Sales and Marketing FDA, Intellipharma, biotech, drugs, pharma, pharmaceutical
The FDA has been very public in its stance that it will look to gain the upper hand in bringing …
Pangea X: the largest coordinated operation against counterfeit drugs
September 26, 2017Manufacturing and Production, Sales and Marketing Europol, FDA, biotech, drugs, interpol, pharma, pharmaceutical
Operation Pangea X represents an anniversary, of sorts – as it stands as the 10th year of operations by Interpol …
Pfizer sets up its own biotech to develop rejected drugs
September 26, 2017Manufacturing and Production, Sales and Marketing Pfizer, SpringWorks Therapeutics, biotech, drugs, pharma, pharmaceutical
Pfizer has moved to set up an entirely independent company to develop four of its own clinical-stage drug candidates. The …
Allergan posts disappointing data in NASH
September 25, 2017Research and Development, Sales and Marketing Allergan, biotech, drugs, nash, pharma, pharmaceutical
It was only last year that Allergan decided to cough up $1.7 billion to acquire Tobira Therapeutics, with the main …
‘Super malaria’ sweeps South East Asia
September 25, 2017Medical Communications, Sales and Marketing biotech, drug resistance, drug-resistance, drugs, malaria, pharma, pharmaceutical
There has long been concern over cases of drug-resistant malaria emerging in Asia and now it has been revealed that …
FDA rejects J&J’s treatment for rheumatoid arthritis
September 25, 2017Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, sirukumab
Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned …
Alnylam soars on likely first RNAi treatment approval
September 22, 2017Medical Communications, Research and Development Alynylam, Sanofi, biotech, drugs, patisran, pharma, pharmaceutical
Alnylam has been plugging away in the RNAi-based treatment area for 15 years and, finally, has something to show for …
19 deaths from liver drug causes Intercept shares to tumble
September 22, 2017Medical Communications, Sales and Marketing Intercept Pharmaceuticals, Ocliva, biotech, drugs, pharma, pharmaceutical
Intercept Pharmaceuticals had sparked major concerns over its drug, Ocaliva, after it revealed that 10 people had died as a …
New therapy offers triple threat to HIV virus
September 22, 2017Medical Communications, Research and Development HIV, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and the National Institutes of Health (NIH) have combined to create a potential HIV therapy that was shown to …
Witty, Ex-CEO of GSK, keeps busy with two new roles in two days
September 21, 2017Medical Communications : Pharma, Andrew Witty, GSK, biotech, drugs, pharma, pharmaceutical
It was always unlikely that Andrew Witty, former CEO of GSK, would take his ‘retirement’ from the company literally, but …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
